Abstract:
본 발명은 면역증강용 조성물, 면역원성을 가지는 에피토프, 이들의 스크리닝 방법 및 이들의 제조방법과, 단백질 항원에 대한 항체, 이들의 스크리닝 방법 및 이들의 제조방법에 관한 것이다. 본 발명의 조성물은 면역강화를 통해 암, 인플루엔자 바이러스, C형 간염 바이러스, RSV(repiratory syncytial virus) 같은 다양한 면역-결핍 관련 질환의 예방 또는 치료에 유용하게 이용될 수 있다.
Abstract:
PURPOSE: An immunostimulatory composition containing liposome-encapsulated oligonucleotides as active ingredients is provided to prevent and treat various immune deficiency diseases and to be used as an immunoadjuvant. CONSTITUTION: An immunostimulatory composition contains liposome-encapsulated immunostimulatory oligonucleotides as active ingredients, containing dioleyl phosphatidylethanolamine (DOPE) and cholesteryl hemisuccinate (CHEMS). The immunostimulatory oligonucleotides are CpG oligonucleotides with a nucleotide sequence of sequence number 1 or CpT oligonucleotide with nucleotide sequences selected from sequence numbers 2-49. The immunostimulatory oligonucleotides are CpT oligonucleotides with nucleotide sequences selected among sequence numbers 2, 3, 4, 19, 24, 39, and 46-49.
Abstract:
PURPOSE: An immunostimulatory composition containing liposome-encapsulated oligonucleotides including DOPE and CHEMS is provided to treat and prevent diseases relating to immunological deficiency. CONSTITUTION: An immunostimulatory composition contains liposome-encapsulated immunostimulatory oligonucleotides as an active ingredient, including DOPE(dioleyl phosphatidylethanolamine) and CHEMS(cholesterylhemisuccinate). The immunostimulatory oligonucleotide is CpG oligonucleotide or CpT oligonucleotide. The composition contains the CpT oligonucleotide including a nucleotide sequence of general formula 1(CTX1X2CTX3X4X5CT) or 2(CTX1X2X3CTX4X5X6CT).
Abstract:
본 발명은 피부 감작제에 의해 발현되는 MIP-2 에 의해 유도되는 아토피 피부염을 치료할 수 있는 치료제 개발에 이용할 수 있는 방법에 관한 것으로, 더욱 상세하게는 피부 감작제(예를 들어, DNFB)가 대식세포를 자극하여 키모카인인 MIP-2 (macrophage inflammatory protein-2) 의 발현을 증가시켜 아토피 피부염을 유발하는 과정에서 이를 조절하는 물질을 탐색하는 방법에 관한 것이다. DNFB, MIP-2, 아토피 피부염
Abstract:
PURPOSE: A composition for treating skin inflammatory diseases caused by UV irradiation, which contains cordycepin is provided to prevent skin damage and suppress inflammation. CONSTITUTION: A composition for treating skin injury caused by skin inflammation by ultra violet B (UVB) contains a cordycepin as an active ingredient. A composition for treating treats skin inflammation and skin injury according to increase of oxygen free radical by UV. A composition for preventing prevents skin inflammation.
Abstract:
A method of screening a candidate material of treating atopic dermatitis is provided to search a treating matter suppressing the expression of MIP-2(macrophage inflammatory protein-2) by a skin sensitizer such as DNFB. A method of screening a candidate material of treating atopic dermatitis comprises the steps of: (a) processing a skin sensitizer to macrophage independently; (b) processing the skin sensitizer and the candidate material to macrophage; and (c) comparing MIP-2 expression at the step (a) and step (b) in macrophage. The MIP-2 protein has an amino acid sequence stated in SEQ ID NO:1. Macrophage is RAW 264.7 cell. The skin sensitizer is selected from the group consisting of DNFB(2,4-dinitrofluorobenzene), DNCB(2,4-dinitrochlorobenzene), and TNBS(2,4,6-trinitrobenzene sulfonic acid).